Black seed oil from TriNutra may help relieve itchy, scaly skin and scalp, according to recent study

The study found that subjects with mild to moderate seborrhea of the scalp saw a significant 58.8.% reduction in erythema scores and a substantial 30% decrease in scaling scores after 28 days of using a 5% B’utyQuin Scalp Serum.

TriNutra (Harrison, NY) has announced that publication of a human clinical trial1 demonstrating the impact its proprietary black seed oil ingredient, B’utyQuin, has on irritated, itchy, scaly skin and scalp, as well as seborrheic dermatitis. Prior to this current trial, in vitro research found that B’utyQuin’s constituents act synergistically to maximize mitochondrial function, metabolism, energy (ATP) production, and exhibited anti-inflammatory, antioxidant, and antimicrobial benefits. When tested against other black seed oil ingredients, B’utyQuin was shown to have superior antifungal properties due to tis high (3%) thymoquinone content and low free fatty acid content.

In the current blinded, controlled, single-center study, male and female subjects between the ages of 18 and 65 with mild to moderate seborrhea of the scalp saw a significant 58.8.% reduction in erythema scores and a substantial 30% decrease in scaling scores after 28 days of using a 5% B’utyQuin Scalp Serum.

“After the positive results from our in vitro testing and the publication of our first study demonstrating B’utyQuin’s ability to aid in aging skin, we were thrilled to see the continuation of B’utyQuin’s potent effects on the skin and scalp,” said Morris Zelkha, CEO of TriNutra, in a press release. “Not only did B’utyQuin improve symptoms of seborrheic dermatitis such as redness, itchiness, scaling, and flaking of the scalp, but it also had soothing properties and reduced scalp oiliness.”

Reference

  1. Oppen-Bezalel, L. von et al. “Irritated, itchy, scaly, seborrheic scalp: Causes and relief with a proprietary, cold-pressed Nigella sativa (Black Seed) oil, standardized to 3% thymoquinone.” SOFW Journal, no. 148 (2022)